A Review on Pediatric Adverse Effects of First Line Anti-Tubercular Drugs

  • B A
  • Sreejith K
  • Thasneem K
  • et al.
N/ACitations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

Tuberculosis is a potentially serious communicable disease caused by mycobacterium tuberculosis. That mainly affects lungs. Tricky mitigation and diagnosis cause the childhood tuberculosis a growing burden for society. Directly Observed Treatment Short course (DOTS) strategy is one of the largest public health programmes found to be beneficial against tuberculosis. Anti-tubercular treatment shows greater level of efficacy high degree of toxicity; however combination treatment, especially during the intensive phase of therapy may produce severe adverse events. First line therapy of Tuberculosis leads to serious adverse effects. Serious adverse effects are less in children receiving drug therapy. Major adverse event associated with anti TB drugs is hepatotoxicity. Keywords: Tuberculosis, DOTS, isoniazid, rifampicin, pyrazinamide, ethambutol and streptomycin

Cite

CITATION STYLE

APA

B, A., Sreejith, K., Thasneem, K. V. M., Maniyan, N., Faris, P. P. M., & Neena, C. C. (2020). A Review on Pediatric Adverse Effects of First Line Anti-Tubercular Drugs. Journal of Drug Delivery and Therapeutics, 10(6), 216–218. https://doi.org/10.22270/jddt.v10i6.4544

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free